Definitive Contract HHSD200201692313C

Award Date 9/30/16
Potential Completion Date 9/29/20
Potential Value $1.5M
Federal Agency
CDC Pittsburgh
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Phoenix, AZ 85004, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This contract was awarded by the Department of Health and Human Services Centers for Disease Control and Prevention (CDC) to the Translational Genomics Research Institute (TGen), a non-profit research organization. The contract, valued at $109,504.00, is a Definitive Contract with a Firm Fixed Price under Broad Agency Announcement (BAA) 2017. The contract does not have a set-aside designation. Under this contract, TGen will provide a variety of genomic research services, including SARS-CoV-2...
This is a $1,074,709 firm fixed-price definitive contract awarded to the Translational Genomics Research Institute (TGen), a non-profit research organization, by the Centers for Disease Control and Prevention (CDC) for the FY 21 BAA TOPIC 8 - TGRI project. The contract has a period of performance through May 14, 2023 and was awarded on May 15, 2021 with no set-aside designation. TGen is a leading institute in precision medicine and translational bioscience, specializing in genomic analyses,...
This is a $145,000.00 firm fixed-price purchase order contract awarded by the Department of Health and Human Services Centers for Disease Control and Prevention to the Translational Genomics Research Institute (TGen), a non-profit research organization. The contract is for RUN DATA SAMPLES services, with a completion date of September 29, 2024. TGen has previously performed genomic research services for federal agencies under both contracts and grants, including work related to SARS-CoV-2,...
This is a $77,025 purchase order contract awarded by the Indian Health Service, a civilian agency within the U.S. Department of Health and Human Services, to the Translational Genomics Research Institute (TGen) for COVID-19 (SARS-CoV-2) testing and translational genomics research. The contract does not have a set-aside designation. TGen is a non-profit biomedical research organization that specializes in genomic analysis and bioinformatics to advance precision medicine. Through this contract,...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, awarded a $7,224,693.00 definitive cost contract to the Translational Genomics Research Institute (TGen), a non-profit biomedical research organization. The contract is for "MYCOBACTERIUM TUBERCULOSIS PROTEOME-WIDE EPITOPE DISCOVERY AND HOST TRANSCRIPTOME-WIDE T CELL PHENOTYPING IN HIGH DISEASE BURDEN POPULATIONS" and has an ultimate completion date of September 29, 2025. The contract does not have...
This is a firm fixed-price purchase order awarded by the Department of Health and Human Services Indian Health Service to the Translational Genomics Research Institute (TGen), a non-profit research organization, for the provision of 1,000 SARS-CoV-2 nasopharyngeal PCR tests at $51.35 per test, for a total potential value of $205,400. The contract does not have a set-aside designation and was awarded in response to the COVID-19 National Interest Action. TGen has a history of providing genomic...
This is a $3,202,949.00 federal contract awarded by the Department of Homeland Security (DHS) Science and Technology Directorate to the Translational Genomics Research Institute (TGen), a non-profit biomedical research organization. The contract is for research and development services to develop and validate a field-ready multiple amplicon sequencing system for detecting and characterizing five biothreat agents: Bacillus anthracis, Francisella tularensis, Yersinia pestis, Burkholderia...
The Centers for Disease Control and Prevention (CDC) awarded a $716,320 purchase order to Theiagen Consulting LLC, doing business as Theiagen Genomics, for TERRA SUPPORT under its major program code for Communicable Disease. Theiagen Genomics will provide genomics support services from its location in Highlands Ranch, Colorado to the CDC in Pittsburgh, Pennsylvania over the one-year period beginning September 8, 2021 through August 14, 2022. The contract utilizes firm fixed pricing for the...
The United States Department of Agriculture Animal and Plant Health Inspection Service (USDA APHIS) awarded a $5.34 million firm fixed price definitive contract to Translational Genomics Research Institute, doing business as TGen Research Institute, to conduct SARS-CoV-2 sample collection and biosecurity assessments in wildlife rehabilitation facilities. The contract will be performed in Phoenix, Arizona over a period of performance from July 1, 2023 through December 31, 2025. No...
This is a $162,500 firm-fixed-price definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to Phase Genomics Inc., a biotechnology company specializing in advanced genomic sequencing and analysis services. The contract is for work related to "NCEZID in Biotechnology" and does not have a set-aside designation. Phase Genomics has previously received federal grants, primarily from the National Institutes of Health, to develop novel genomic technologies and...

This federal contract award, valued at $1,472,866.08, was issued by the Centers for Disease Control and Prevention (CDC) to the Translational Genomics Research Institute (TGen), a non-profit biomedical research organization. The contract provides bioinformatics support services, including genomic sequencing, analysis, and data services, to advance precision medicine research. TGen has previously conducted genomic research and analysis work for several federal agencies, such as the National Institute on Aging, the U.S. Department of Agriculture, and the Department of Veterans Affairs. While this contract does not have a set-aside designation, TGen often collaborates with other research organizations as both a prime contractor and subcontractor to deliver comprehensive genomic research services. The award contributes to TGen's broader portfolio of federal grants across various disease areas, including type 1 diabetes, Alzheimer's disease, and glioblastoma.

Generated 4/1/25, 4:32 PM